Qureight provides AI-powered imaging contract research organization (CRO) services for clinical trials, specializing in lung and heart disease.
qureight.comLinkedInStation Road, nullHealthtechFounded 2018
13 sources
Business Weekly dates the announcement 28 July 2026, while Qureight’s own release dates it 29 July 2026; the company release takes precedence. The headquarters source states Cambridge but does not state a country.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $20M | 2026-07-29 | Molten Ventures | No recent discussion |
13 sources [ VERIFIED ] read against 4 of 13 sources Business Weekly dates the announcement 28 July 2026, while Qureight’s own release dates it 29 July 2026; the company release takes precedence. The headquarters source states Cambridge but does not state a country. | ||||
Qureight builds an AI-powered imaging CRO and data-analysis platform that helps biopharma sponsors run faster clinical trials for lung and heart disease.
Clinical-trial imaging and patient records can be scattered across platforms, making manual extraction expensive and slowing development; Qureight says its integrated imaging CRO, AI biomarkers, and data products structure that evidence and can enable faster patient selection, endpoint assessment, and trial decisions. The $20 million Series B matters because it funds a 3D chest Foundation Model and AI imaging lab, new disease models beyond lung fibrosis, and commercial scaling as the company reports services already being used by biopharma partners.
Checked against 10 sources yesterday
Also named as backers in company research: Playfair Capital, Ascension Life Fund, Cambridge Angels